| Literature DB >> 35812426 |
Pandiarajan Vignesh1, Gummadi Anjani1, Rajni Kumrah1, Ankita Singh1, Sanjib Mondal1, Johnson Nameirakpam1, Ankur Jindal1, Deepti Suri1, Madhubala Sharma1, Gurjit Kaur1, Sathish Sharma1, Kirti Gupta2, Sreejesh Sreedharanunni3, Amit Rawat1, Surjit Singh1.
Abstract
Background: Hemophagocytic lymphohistiocytosis (HLH) is characterized by uncontrolled and excessive inflammation leading to high mortality. Aetiology of HLH can be primarily due to genetic causes or secondarily due to infections or rheumatological illness. However, rarely T-cell deficiencies like severe combined immunodeficiency (SCID) can develop HLH. Objective: To describe clinical and laboratory features of SCID cases who developed HLH.Entities:
Keywords: BCG; X-linked; family history; hemophagocytic lymphohistiocytosis; infections; severe combined immunodeficiency
Mesh:
Year: 2022 PMID: 35812426 PMCID: PMC9260510 DOI: 10.3389/fimmu.2022.867753
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 8.786
Review of literature of previously reported cases of HLH in SCID patients.
| Author/Ref. | Genetic | Age (median age (IQR)/Sex | Infections | HLH onset age | HLH features | Management of HLH | HSCTY/N | Outcome |
|---|---|---|---|---|---|---|---|---|
| Chidambaram et al., 2020India ( | Homozygous missense variation in | 3 month/F | CMV PCR positivity (bloodand urine) | 3 months | Anemia, | IVIgDexamethasone; Ganciclovir | No | Expired |
| Bode et al., 2015 | 12 patients | NA | CMV (n = 3), adenovirus (n = 3), EBV ( | 0.13-1.5 years | – | Corticosteroids alone or in | NA | 8 Expired |
| Cetinkaya, | 4 patients | 2.5 months (2-5 months) | CMV (n = 3) and parainfluenza 3 (n = 1) | 4.5 months (2-22 months) | – | Corticosteroids alone or in | Y (N = 1) | Expired 3 |
| Shi et al., 2020; China | IL2RG gene (Exon 6: c.854G > A; | 4 month/M | 4 months (Day 8 of HS) | Low fibrinogen (0.91 g/L); high | One intravenous etoposide | No | Expired | |
| Patirgolu et al., 2014 | IL2RG gene; the novel | 3 month/M | 3 month, (3rd week of HS) | Elevated transaminases, | IVIG, broad-spectrum antibiotics, ATT | No | Expired | |
| Grunebaum et al., 2000 | IL2RG | 9 week/M | NA | 9 weeks (at onset) | Pancytopenia | Etoposide and dexamethasone | No | Expired; Gram-negative septicemia |
| Alsalamah., | Homozygous mutation | 6 month/F | Adenovirus (nasopharyngeal swab); urine culture | 6 months (at onset) | Anemia (Hb 88 g/L), thrombocytopenia; leukopenia; high ferritin (>100,000 μg/L), elevated triglyceride | Dexamethasone, IVIG, | No | Expired 2 weeks |
| Suzuki et al., | NA | 19 d/F | – | 5/8 HLH | IVIG, corticosteroid, cyclosporine, etoposide, HSCT | Y | Expired | |
| Schimid et al. | (T−, B+, | 5 month/M | Active EBV infection was diagnosed by quantitative PCR | 6 days of HS | Anemia, thrombocytopeniaand leukocytosis; | Dexamethasone | Y | Expired |
| Dvorak et al., | X-linked SCID | 7 week/M | Methicillin-sensitive | 7 weeks of life | Bone marrow | IVIG, 2-week course of cyclosporine (3 mg/kg/dose | Y | Well at 17 months |
| Klemann et al., | ORAI1 | 6 weeks/M | CMV infection was diagnosed based on of blood virus loads >100.000 IU/ml | 3 months of age at presentation | Pancytopenia; hyperferritinemia (5103ng/ml), hypertriglyceridemia (371 mg/dl = 4.1 mmol/l), hypofibrinogenemia (1.4 g/l) and elevated soluble CD25 (max. 4022 U/l). | Treatment with dexamethasone improved the HLH symptoms, but the patient relapsed upon tapering | Y | Expired |
| Norris et al., | IL2RG | 5 month/M | Post-HSCT | Pancytopenia; | 4 weekly doses | Y | Chimerism continues to be | |
| Tucci, 2021 | ADA SCID | 4 year/F | Post 2nd HSCT (D+13) | Persistent fever, hepatosplenomegaly, high levels | Methylprednisolone | Y; 3 HSCT | Alive after 3rd HSCT | |
| Hashi et al., 2010 China | Novel homozygous | 5 month/f | NA | Post HSCT (Day 18) | Cytopenia; BM aspiration revealed hypoplastic | Etoposide 30 mg/m2 and pulse methylprednisolone (30 mg/kg) | Y | Expired Day 32 post-HSCT |
| Singh et al., 2020 | IL2RG | 10 day/M | Human herpes virus 6 | 10 days of life | Fever and pancytopenia with elevated ferritin (1251 ng/mL) | Dexamethasone | Y | Alive |
NA, Not available
Clinical and laboratory features of HLH in patients with SCID from our cohort.
| Investigations /clinical | P1 | P2 | P3 | P4 | P5 | P6 |
|---|---|---|---|---|---|---|
| Fever | Yes | Yes | Yes | Yes | Yes | Yes |
| Splenomegaly | Yes | Yes | No | Yes | Yes | Yes |
| Hemoglobin (g/L) | 7.1 | 4.6 | 6.5 | 9.8 | 6.2 | 5 |
| Total leucocyte count (× 109 /L) (N: 4-11) | 2.14 ↓ | 2.34 ↓ | 35.4 ↑ | 4.17 | 15 | 18.8 ↑ |
| Differential leucocyte counts (N%/L% /M%/E%) | 85/6/8/0 | 81/16/2/1 | 92/6/0/2 | 85/9/5/0 | 69/25/6/0 | 90/5/3/2 |
| Platelet counts (×109 /L) (N: 150-450 ×109 /L) | 21 ↓ | 4 ↓ | 16 ↓ | 150 ↓ | 93 ↓ | 14 ↓ |
| CRP (mg/L) (N: <10) | 90 | 204 | 144 | 78.58 | NA | NA |
| ESR (mm/1st hour) | NA | 2 | NA | NA | NA | NA |
| Ferritin (ng/ml) | 3365 ↑ | 967 ↑ | 36016 ↑ | >2000 ↑ | 61900 ↑ | NA |
| Fibrinogen (g/L) | <0.4 ↓ | 2.12 | <0.35 ↓ | 0.46 ↓ | 1.08 ↓ | NA |
| Triglyceride (mg/dl) | 217 ↑ | NA | 172 ↑ | 255 ↑ | >500 ↑ | NA |
| Aspartate Transferase (IU/L) (N:15-50) | 283 ↑ | 246 ↑ | 2988 ↑ | 133 ↑ | 2280 ↑ | 604 ↑ |
| Alanine Transferase (IU/L) (N:12-45) | 49 | 72 ↑ | 378 ↑ | 116 ↑ | 609 ↑ | 50 |
| Bone marrow | NA | hemophagocytosis | NA | hemophagocytosis | hemophagocytosis | Erythrophagocytosis |
| Soluble CD25 | NA | 89.47 IU/ml (27-189 IU/ml) | NA | NA | NA | NA |
| HLH 2004 Criteria | Yes | Yes | No | Yes | Yes | No |
| HLH diagnosed on | Day 1 | Day 7 HS | Day 1 | Day 9 | D5 HS | Post mortem/Autopsy |
P, patient; N, neutrophils; L, lymphocytes; M, monocytes, E, eosinophils; HLH, hemophagocytic lymphohistiocytosis; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; HS, hospital stay, High Low. NA, Not available.
Immunological work-up of patients with SCID and HLH-like manifestations at the time of SCID diagnosis.
| Immunological work up | P1 | P2 | P3 | P4 | P5 | P6 |
|---|---|---|---|---|---|---|
| Hemoglobin(g/L | 7.1 | 5.3 | 6.4 | 9.8 | 6.2 | 5 |
| Total leucocyte count (× 109 /L) (N: 4-11) | 2.14 ↑ | 14.9 ↓ | 9.5 | 4.17 | 22.6 ↑ | 18. 8 ↑ |
| Differential leucocyte counts (N%/L%/M%/E%) | 85/6/9/0 | 85/14/0.9 /0.1 | 92/6/0/2 | 85/9/4/2 | 87/8/3/2 | 90/5/3/2 |
| Platelet counts (× 109 /L) (N: 150-450 ×109 /L) | 21 ↓ | 95 ↓ | 390 | 150 | 276 | 14 ↑ |
| 0.128 | 2.086 | 0.285 | 0.375 | 1.8 | 0.940 | |
| 2.46% (49-76% | 0.61% (51-77%) | 82.87% | 1.7% (15-77%) | 95.65% (49-76%) | Absent | |
| 87% | 97.82% (11-41%) | 5.69% | 91.57% | 1.78% | 86% | |
| 2.51% | 0.22% | 5.63% | 2.68% | 0.53% | NA | |
| 0.64% | 0.04% | 2.07% | 0.05% | 1.69% | NA | |
| – | – | 89.37% | 81.8% | 97.91% | – | |
| – | – | 12.07% | 00.16% | 0.34% | – | |
| – | – | Mild increase (15.1%) as compared to healthy control (10.18%) | – | Increased | – | |
| Decreased on lymphocytes (12.07%) as compared to control (40.53%) | Decreased on lymphocytes 25.23% as compared to control (83.53%) | – | – | Decreased on lymphocytes (67.8% vs 88.3%) and monocytes (59.7% vs 88.9%) | – | |
| – | IgG: <1.46 (2.40-8.80) | – | IgG 0.232 | IgG <0.202 | IgG <0. 294 | |
| NA | NA | NA | NA | No maternal engraftment | NA | |
| IL2RG |
P, patient; N, neutrophils; L, lymphocytes; M, monocytes, E, eosinophils; VNTR, variable number of tandem repeats. NA, Not available.
Figure 1(A) A large collection of foamy macrophages in the dermis (scale bar 20 µm); (B) low magnification depicting numerous acid-fast bacilli within the foamy cells in the dermis (ZN, scale bar 50 µm); (C) Numerous acid fast bacilli within the dermis both intra- and extra-cellularly (ZN, scale bar 20 µm); (D) Hemophagocytosis within Kupffer cells in the sinusoids (arrow) (H&E, scale bar 20 µm).
Clinical features of patients with HLH-like features in SCID in our series.
| Parameters | P1 | P2 | P3 | P4 | P5 | P6 |
|---|---|---|---|---|---|---|
| Family history | Yes | No | Yes | No | Yes | Yes |
| Age of onset (months) | 5 | 4 | 2 | 5 | 4.5 | 3 |
| Age of diagnosis (months) | 6 | 5 | 3 | 6 | 6 | 6.5 |
| Delay of diagnosis (months) | 1 | 1 | 1 | 1 | 1.5 | 3.5 |
| HLH (months) | 6 | 5 | 3 | 6 | 6 | 6.5 |
| BCG site | No scar | Ulcerated | No scar | Normal scar | Normal scar | No scar |
| History of blood transfusions | No | No | Yes | Yes | Yes | No |
| Rash | No | Yes (BCG) | Yes (post-transfusion) | Yes | Yes | No |
| Omenn/GVHD/maternal engraftment | No | No | GVHD (secondary to blood transfusion) | Omenn syndrome | Omenn syndrome | No |
| Infection | Pneumonia | Pneumonia | Pneumonia | Pneumonia | Pneumonia | Recurrent pneumonias |
| Organism isolated by microbiological methods | Blood culture: | Disseminated BCG infection | Blood culture staphylococcus aureus | H1N1; | No organism | Disseminated BCG in thymus, lungs, lymph nodes, spleen, liver, kidney, bone marrow |
| Treatment regimen/Immunomodulation | IVIg 1g/kg | IVIg 1g/kg | IVIg 2 g/kg | IVIg | IVIg | IV antimicrobials |
Detailed genetic reports of SCID patients with HLH in the present series.
| Patient | Gene | Exon | Protein position | c.DNA | Inheritance pattern | Type | Novelty | Pathogenicity |
|---|---|---|---|---|---|---|---|---|
| P1 | IL2RG | Intron 7 | c.924+1 G>A | X-Linked | Splice –site (Hemizygous) | Yes | Pathogenic | |
| P2 | IL2RG | 5 | p.E199VfsX76 | c.596_598delinsTGGATTAT | X-Linked | Hemizygous –Frameshift | Previously reported | |
| P3 | NA | |||||||
| P4 | IL2RG | 8 | p.Q322X | c.964C>T | X-Linked | Nonsense (Hemizygous) | Previously reported (7) | Pathogenic |
| P5 | IL2RG | 4 | p.V152A | c.455 T>C | X-Linked | Missense (Hemizygous) | Previously reported (7) | Pathogenic |
| P6 | IL2RG | 4 | p.L172R | c.515T>G | X-Linked | Missense (Hemizygous) | Previously reported (7) | Pathogenic |
Figure 2(A-E) Bone marrow aspirate showing histiocytes with pseudopods and vacoules, phagocytosed red cells (red arrow), platelets (blue arrow), and lymphocyte (green arrow) (May Grunwald Giemsa stain 100x); (F, G) markedly hypocellular bone marrow biopsy with marked reduction of all normal hematopoietic cells. A histocyte is visible with phagocytosed neutrophil (black arrow) (Hematoxylin and Eosin, F - 20x and G - 100x).